Ovarian germ cell malignancies: the Yale University experience

Gynecol Oncol. 1992 Apr;45(1):26-31. doi: 10.1016/0090-8258(92)90486-3.
No abstract available

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / standards
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bleomycin / administration & dosage
  • Bleomycin / adverse effects
  • Bleomycin / standards
  • Cisplatin / administration & dosage
  • Cisplatin / adverse effects
  • Cisplatin / standards
  • Combined Modality Therapy
  • Cyclophosphamide / administration & dosage
  • Cyclophosphamide / adverse effects
  • Cyclophosphamide / standards
  • Dactinomycin / administration & dosage
  • Dactinomycin / adverse effects
  • Dactinomycin / standards
  • Etoposide / administration & dosage
  • Etoposide / adverse effects
  • Etoposide / standards
  • Female
  • Fertility / drug effects
  • Humans
  • Neoplasms, Germ Cell and Embryonal / drug therapy
  • Neoplasms, Germ Cell and Embryonal / surgery
  • Neoplasms, Germ Cell and Embryonal / therapy*
  • Ovarian Neoplasms / drug therapy
  • Ovarian Neoplasms / surgery
  • Ovarian Neoplasms / therapy*
  • Salvage Therapy
  • Vinblastine / administration & dosage
  • Vinblastine / adverse effects
  • Vinblastine / standards
  • Vincristine / administration & dosage
  • Vincristine / adverse effects
  • Vincristine / standards

Substances

  • Bleomycin
  • Dactinomycin
  • Vincristine
  • Vinblastine
  • Etoposide
  • Cyclophosphamide
  • Cisplatin

Supplementary concepts

  • BEP protocol
  • PVB protocol
  • VAC protocol